Keros Therapeutics, Inc.

NasdaqGM:KROS Stok Raporu

Piyasa değeri: US$238.1m

Keros Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Keros Therapeutics CEO'su Jas Seehra, Dec2015 tarihinde atandı, in görev süresi 10.58 yıldır. in toplam yıllık tazminatı $ 2.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.6% maaş ve 72.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.88% ine doğrudan sahiptir ve bu hisseler $ 4.49M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.3 yıl ve 4.4 yıldır.

Anahtar bilgiler

Jas Seehra

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi27.56%
CEO görev süresi10.6yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi6.3yrs
Yönetim Kurulu ortalama görev süresi4.4yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Nov 18

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Aug 21

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Summary Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven. Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects. Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance. Read the full article on Seeking Alpha
Analiz Makalesi • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...
Analiz Makalesi • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...
Analiz Makalesi • May 09

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shares have had a really impressive month, gaining 44% after a shaky period...
Seeking Alpha • Mar 13

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Summary Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Summary Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda Pharmaceutical Company for elritercept and its potential $900m annual revenue offers a safety net. The market reaction may be too harsh; past biotech clinical study setbacks have often been resolved, presenting a contrarian investment opportunity. Investors should wait for more data on cibotercept's safety issues before making definitive judgments. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 20

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Aug 07

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jun 10

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029. Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 23

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Key Insights The projected fair value for Keros Therapeutics is US$94.52 based on 2 Stage Free Cash Flow to Equity...
Analiz Makalesi • Sep 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Jun 10

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 04

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release (NASDAQ:KROS): Q2 GAAP EPS of -$1.13 misses by $0.07. Cash and cash equivalents OF $215.62M
Analiz Makalesi • Apr 29

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jan 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Oct 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Tazminat Analizi

Jas Seehra'un ücretlendirmesi Keros Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$85m

Dec 31 2025US$3mUS$700k

US$87m

Sep 30 2025n/an/a

US$64m

Jun 30 2025n/an/a

US$19m

Mar 31 2025n/an/a

US$4m

Dec 31 2024US$6mUS$699k

-US$187m

Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

Tazminat ve Piyasa: Jas 'nin toplam tazminatı ($USD 2.54M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.61M ).

Tazminat ve Kazançlar: Jas 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jas Seehra (70 yo)

10.6yrs
Görev süresi
US$2,540,204
Tazminat

Dr. Jasbir S. Seehra, also known as Jas, Ph D., is President of Keros Therapeutics, Inc. from August 18, 2025 and has been its Chief Executive Officer and Director since December 2015 and was its Chair of...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jasbir Seehra
President10.6yrsUS$2.54m1.88%
$ 4.5m
Keith Regnante
Chief Financial Officer6.4yrsUS$1.11m0.049%
$ 117.7k
Esther Cho
Chief Legal Officer & Secretary6.3yrsUS$1.10m0.20%
$ 478.3k
Justin Frantz
Head of Investor Relationsno dataVeri yokVeri yok
Lorena Lerner
Chief Scientific Officerless than a yearVeri yok0.16%
$ 374.5k
6.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş

Deneyimli Yönetim: KROS 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jasbir Seehra
President10.6yrsUS$2.54m1.88%
$ 4.5m
Jean-Jacques Bienaime
Independent Chair of the Board2.1yrsUS$259.44k0.053%
$ 125.7k
Julius Knowles
Independent Director10.3yrsUS$239.04k0.019%
$ 45.9k
Mary Gray
Independent Director5.6yrsUS$247.54k0.30%
$ 702.8k
Alpna Seth
Independent Director3.2yrsUS$238.54k0.18%
$ 432.6k
Anne Prener
Directorno dataVeri yokVeri yok
Nima Farzan
Independent Director6.3yrsUS$239.04k0.24%
$ 574.0k
Charles Newton
Independent Directorless than a yearVeri yok0.064%
$ 152.4k
4.4yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: KROS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/07/10 08:57
Gün Sonu Hisse Fiyatı2026/07/10 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Keros Therapeutics, Inc. 16 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.